March 13, 2026 by Mohr Marketing
The $3B Liquidity Advantage: Why Depo-Provera is the Strategic Play for 2025-2026 As many mass torts face defendants with thinning capital, the Depo-Provera litigation stands out for its defendant solvency. Pfizer holds massive liquidity, providing the “muscle” to absorb a global settlement without the existential risks seen in other recent litigations. A Mature Docket with…
Continue reading Why Depo-Provera is the Strategic Play for 2025-2026
March 12, 2026 by Mohr Marketing
Beyond “Intake Noise”: Why Precision is the Only Way to Build a Depo-Provera Docket The pharmaceutical liability landscape has shifted with the emergence of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the numbers are massiveโan estimated 74 million users worldwideโthe legal viability of these cases hinges on a level of medical precision that…
Continue reading Why Precision is the Only Way to Build a Depo-Provera Docket
March 11, 2026 by Mohr Marketing
MDL 3140: Is Your Intake Ready for the Depo-Provera Docket? In an era where some mass tort defendants are thinly capitalized or seeking bankruptcy protection, the Depo-Provera litigation offers a rare strategic advantage: Defendant Solvency. Pfizer, the primary defendant, holds massive liquidity, giving them the “muscle” to absorb a global settlement without existential risk to…
Continue reading Defendant Solvency and the Business Case for MDL 3140
March 10, 2026 by Mohr Marketing
The Precision Mandate: Why Medical Integrity is the Only Path to a Defensible Depo-Provera Docket The pharmaceutical liability landscape shifted significantly with the consolidation of MDL 3140 (In re: Depo-Provera Products Liability Litigation). While the sheer scale of the potential plaintiff poolโestimated at 74 million usersโis a headline-grabber, the true story of this litigation lies…
Continue reading Medical Integrity the Only Path to Defensible Depo-Provera Docket
March 2, 2026 by Mohr Marketing
Mohr Marketing Redefines Motor Vehicle Accident Case Acquisition with Exclusive Police Report Data Strategy and AI-Driven DPPA Compliance ALLENTOWN, PA โ Mohr Marketing, LLC, a leader in B2B client acquisition for legal professionals, officially announces the launch of its groundbreaking Police Report-Backed MVA Case Acquisition Program. This innovative strategy leverages direct access to official law…
Continue reading Scalable MVA Case Acquisition: AI-Driven Police Report Strategies
February 28, 2026 by Mohr Marketing
Direct-from-Source Data | Law Enforcement Partnership | Nationwide Scale In a market saturated with unverified digital leads, Mohr Marketing, LLC provides the one thing that truly matters: Certainty. Through our partnership with a major law enforcement-owned agency, we deliver high-value MVA cases backed by official police reports. The Three Pillars of Our Lead Integrity 1.…
Continue reading The Gold Standard in MVA Case Acquisition
February 28, 2026 by Mohr Marketing
Mohr Marketing Deploys AI WebTrackerยฎ to Target High-Value NAION and Verified Gastroparesis Claims Amid New 2026 Medical Evidence As GLP-1 litigation enters a critical juncture, Mohr Marketing, LLC has announced the deployment of enhanced precision-targeting technologies to assist law firms in securing high-value claims. With federal case counts nearing 3,200 actions in MDL 3094 and…
Continue reading The GLP-1 Litigation Landscape has Shifted
February 26, 2026 by Mohr Marketing
The Compliance Shield: Why Diagnostic Proof is the New Gold Standard To qualify for a claim in the 2026 Ozempic (Semaglutide) MDL, the court now requires specific medical evidence to distinguish drug-induced injuries from pre-existing conditions. Use this checklist to determine if a potential claimant meets the February 2026 court standards for Gastroparesis or NAION.…
Continue reading The 2026 GLP-1 Pivot: Securing High-Value, Verified Retainers
February 24, 2026 by Mohr Marketing
Ozempic Litigation Update 2026: The Critical Shift to Objective Proof As of February 2026, the Ozempic litigation (MDL 3094 and the newly formed NAION-specific MDL 3163) has shifted from general “failure to warn” claims to a rigorous, evidence-based phase. The court now requires high-level diagnostic proof to separate drug-induced injuries from pre-existing conditions like diabetic…
Continue reading The 2026 Ozempic Litigation Pivot: From Symptoms to Scintigraphy
February 23, 2026 by Mohr Marketing
The Compliance Choice: Audit-Proof Your GLP-1 Inventory: The “Digital Birth Certificate” Solution The Ozempic (semaglutide) multidistrict litigation (MDL 3094) has entered a high-stakes phase in 2026, with a sharpened focus on medical verification and emerging evidence linking the drug to permanent injuries. Medical Evidence: NAION and Gastroparesis New clinical data is driving the current litigation…
Continue reading Compliant GLP-1 Mass Tort Case Generation: AI-Verified & Signed